Citation: | Hu Yao, Liu Ling. Hypomagnesemia and kidney transplantation: research progress in immune effect and infection risk[J]. ORGAN TRANSPLANTATION. doi: 10.3969/j.issn.1674-7445.2024029 |
[1] |
冼盈, 段智勤, 李衡, 等. 肾移植术后感染病原菌特点及死亡风险[J]. 中国感染控制杂志, 2023, 22(5): 539-546. DOI: 10.12138/j.issn.1671-9638.20233265.
XIAN Y, DUAN ZQ, LI H, et al. Characteristics of infection pathogens and risk of death after kidney trans-plantation[J]. Chin J Infect Control, 2023, 22(5): 539-546. DOI: 10.12138/j.issn.1671-9638.20233265.
|
[2] |
VAN LAECKE S, VERMEIREN P, NAGLER EV, et al. Magnesium and infection risk after kidney transplantation: an observational cohort study[J]. J Infect, 2016, 73(1): 8-17. DOI: 10.1016/j.jinf.2016.04.007.
|
[3] |
BARBAGALLO M, VERONESE N, DOMINGUEZ LJ. Magnesium in aging, health and diseases[J]. Nutrients, 2021, 13(2): 463. DOI: 10.3390/nu13020463.
|
[4] |
BOSMAN W, HOENDEROP JGJ, DE BAAIJ JHF. Genetic and drug-induced hypomagnesemia: different cause, same mechanism[J]. Proc Nutr Soc, 2021, 80(3): 327-338. DOI: 10.1017/S0029665121000926.
|
[5] |
ASHIQUE S, KUMAR S, HUSSAIN A, et al. A narrative review on the role of magnesium in immune regulation, inflammation, infectious diseases, and cancer[J]. J Health Popul Nutr, 2023, 42(1): 74. DOI: 10.1186/s41043-023-00423-0.
|
[6] |
FREEMAN CM, WRIGHT BL, BAUER CS, et al. Cutaneous T-cell lymphoma as a unique presenting malignancy in X-linked magnesium defect with EBV infection and neoplasia (XMEN) disease[J]. Clin Immunol, 2021, 226: 108722. DOI: 10.1016/j.clim.2021.108722.
|
[7] |
DE GROOT PF, KWAKERNAAK AJ, VAN LEEUWEN EMM, et al. Case report: XMEN disease: a patient with recurrent Hodgkin lymphoma and immune thrombocytopenia[J]. Front Med (Lausanne), 2023, 10: 1264329. DOI: 10.3389/fmed.2023.1264329.
|
[8] |
CHAIGNE-DELALANDE B, LI FY, O'CONNOR GM, et alJ. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D[J]. Science, 2013, 341(6142): 186-191. DOI: 10.1126/science.1240094.
|
[9] |
BRAULT J, MEIS RJ, LI L, et al. MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease[J]. Cytotherapy, 2021, 23(3): 203-210. DOI: 10.1016/j.jcyt.2020.08.013.
|
[10] |
LÖTSCHER J, MARTÍ I LÍNDEZ AA, KIRCHHAMMER N, et al. Magnesium sensing via LFA-1 regulates CD8+ Tcell effector function[J]. Cell, 2022, 185(4): 585-602. DOI: 10.1016/j.cell.2021.12.039.
|
[11] |
KAPNICK SM, STINCHCOMBE JC, GRIFFITHS GM, et al. Inducible T Cell kinase regulates the acquisition of cytolytic capacity and degranulation in CD8+ CTLs[J]. J Immunol, 2017, 198(7): 2699-2711. DOI: 10.4049/jimmunol.1601202.
|
[12] |
KANELLOPOULOU C, GEORGE AB, MASUTANI E, et al. Mg2+ regulation of kinase signaling and immune function[J]. J Exp Med, 2019, 216(8): 1828-1842. DOI: 10.1084/jem.20181970.
|
[13] |
HOWE MK, DOWDELL K, ROY A, et al. Magnesium restores activity to peripheral blood cells in a patient with functionally impaired interleukin-2-inducible T cell kinase[J]. Front Immunol, 2019, 10: 2000. DOI: 10.3389/fimmu.2019.02000.
|
[14] |
LIANG HY, CHEN Y, WEI X, et al. Immunomodulatory functions of TRPM7 and its implications in autoimmune diseases[J]. Immunology, 2022, 165(1): 3-21. DOI: 10.1111/imm.13420.
|
[15] |
MAHTANI T, TREANOR B. Beyond the CRAC: Diversification of ion signaling in B cells[J]. Immunol Rev, 2019, 291(1): 104-122DOI: 10.1111/imr.12770.
MAHTANI T, TREANOR B. Beyond the CRAC: Diversification of ion signaling in B cells[J]. Immunol Rev, 2019, 291(1): 104-122DOI: 10.1111/imr.12770.
|
[16] |
GOTRU SK, GIL-PULIDO J, BEYERSDORF N, et al. Cutting edge: imbalanced cation homeostasis in magt1-deficient b cells dysregulates B cell development and signaling in mice[J]. J Immunol, 2018, 200(8): 2529-2534. DOI: 10.4049/jimmunol.1701467.
|
[17] |
QIAO W, WONG KHM, SHEN J, et al. TRPM7 kinase-mediated immunomodulation in macrophage plays a central role in magnesium ion-induced bone regeneration[J]. Nat Commun, 2021, 12(1): 2885. DOI: 10.1038/s41467-021-23005-2.
|
[18] |
STEFANACHE A, LUNGU II, BUTNARIU IA, et al. Understanding how minerals contribute to optimal immune function[J]. J Immunol Res, 2023: 3355733. DOI: 10.1155/2023/3355733.
|
[19] |
LA CARRUBBA A, VERONESE N, DI BELLA G, et al. Prognostic value of magnesium in COVID-19: findings from the COMEPA study[J]. Nutrients, 2023, 15(4): 830. DOI: 10.3390/nu15040830.
|
[20] |
ODLER B, DEAK AT, PREGARTNER G, et al. Hypomagnesemia is a risk factor for infections after kidney transplantation: a retrospective cohort analysis[J]. Nutrients, 2021, 13(4): 1296. DOI: 10.3390/nu13041296.
|
[21] |
REZAZADEH H, SHARIFI MR, SHARIFI M, et al. Magnesium sulfate improves insulin resistance in high fat diet induced diabetic parents and their offspring[J]. Eur J Pharmacol, 2021, 909: 174418. DOI: 10.1016/j.ejphar.2021.174418.
|
[22] |
DE SOUSA MELO SR, DOS SANTOS LR, DA CUNHA SOARES T, et al. Participation of magnesium in the secretion and signaling pathways of insulin: an updated review[J]. Biol Trace Elem Res, 2022, 200(8): 3545-3553. DOI: 10.1007/s12011-021-02966-x.
|
[23] |
杨玉亭, 左庆娟, 郭艺芳. 镁和代谢紊乱[J]. 中国心血管杂志, 2023, 28(2): 189-192. DOI: 10.3969/j.issn.1007-5410.2023.02.019.
YANG YT, ZUO QJ, GUO YF. Magnesium and metabolic disorders[J]. Chin J Cardiovascular Med, 2023, 28(2): 189-192. DOI: 10.3969/j.issn.1007-5410.2023.02.019.
|
[24] |
邢宝迪, 吕文山, 王颜刚, 等. 血清镁与胰岛素抵抗的关系及钠-葡萄糖协同转运蛋白2抑制剂的升镁作用[J]. 中华糖尿病杂志, 2020, 12(7): 543-546. DOI: 10.3760/cma.j.cn115791-20200118-00069.
XING BD, LYU WS, WANG YG, et al. The relationship between serum magnesium and insulin resistance and the effect of sodium-glucose co-transporter 2 inhibitor on magnesium elevation[J]. Chin J Diabetes, 2020, 12(7): 543-546. DOI: 10.3760/cma.j.cn115791-20200118-00069.
|
[25] |
GARNIER AS, DUVEAU A, PLANCHAIS M, et al. Serum Magnesium after Kidney Transplantation: A Systematic Review[J]. Nutrients, 2018, 10(6): 729.DOI: 10.3390/nu10060729.
GARNIER AS, DUVEAU A, PLANCHAIS M, et al. Serum Magnesium after Kidney Transplantation: A Systematic Review[J]. Nutrients, 2018, 10(6): 729.DOI: 10.3390/nu10060729.
|
[26] |
STEFANELLI LF, ALESSI M, BERTOLDI G, et al. Calcineurin-inhibitor-induced hypomagnesemia in kidney transplant patients: a monocentric comparative study between sucrosomial magnesium and magnesium pidolate supplementation[J]. J Clin Med, 2023, 12(3): 752. DOI: 10.3390/jcm12030752.
|
[27] |
VIOLA P, MARCELLI V, SCULCO D, et al. Vestibular disorders after kidney transplantation: focus on the pathophysiological mechanisms underlying the vertical nystagmus associated with tacrolimus-related hypomagnesamia[J]. Int J Environ Res Public Health, 2022, 19(4): 2260. DOI: 10.3390/ijerph19042260.
|
[28] |
PIETROPAOLO G, PUGLIESE D, ARMUZZI A, et al. Magnesium absorption in intestinal cells: evidence of cross-talk between EGF and TRPM6 and novel implications for cetuximab therapy[J]. Nutrients, 2020, 12(11): 3277. DOI: 10.3390/nu12113277.
|
[29] |
MARNEROS AG. Magnesium and calcium homeostasis depend on KCTD1 function in the distal nephron[J]. Cell Rep, 2021, 34(2): 108616. DOI: 10.1016/j.celrep.2020.108616.
|
[30] |
DA SILVA CA, DE BRAGANÇA AC, SHIMIZU MH, et al. Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression[J]. Am J Physiol Renal Physiol, 2009, 297(4): F916-F922. DOI: 10.1152/ajprenal.90256.2008.
|
[31] |
ANDOH TF, BURDMANN EA, FRANSECHINI N, et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506[J]. Kidney Int, 1996, 50(4): 1110-1117. DOI: 10.1038/ki.1996.417.
|
[32] |
崔维恒. 长期使用质子泵抑制剂所致不良反应的研究进展[J]. 河南大学学报(医学版), 2023, 42(3): 163-166,176. DOI: 10.15991/j.cnki.41-1361/r.2023.03.008.
CUI WH. Research progress of adverse reactions caused by long-term use of proton pump inhibitors[J]. J Henan Univ (Med Sci), 2023, 42(3): 163-166,176. DOI: 10.15991/j.cnki.41-1361/r.2023.03.008.
|
[33] |
AYDIN YOLDEMIR Ş, ZEREN OZTURK G, AKARSU M, et al. Is there a correlation between hypomagnesemia linked to long-term proton pump inhibitor use and the active agent?[J]. Wien Klin Wochenschr, 2022, 134(3/4): 104-109. DOI: 10.1007/s00508-021-01834-x.
|
[34] |
SEAH S, TAN YK, TEH K, et al. Proton-pump inhibitor use amongst patients with severe hypomagnesemia[J]. Front Pharmacol, 2023, 14: 1092476. DOI: 10.3389/fphar.2023.1092476.
|
[35] |
GOMMERS LMM, HOENDEROP JGJ, DE BAAIJ JHF. Mechanisms of proton pump inhibitor-induced hypomagnesemia[J]. Acta Physiol (Oxf), 2022, 235(4): e13846. DOI: 10.1111/apha.13846.
|
[36] |
DOUWES RM, GOMES-NETO AW, SCHUTTEN JC, et al. Proton-pump inhibitors and hypomagnesaemia in kidney transplant recipients[J]. J Clin Med, 2019, 8(12): 2162. DOI: 10.3390/jcm8122162.
|
[37] |
郭飘飘, 崔越, 张汝建, 等. 质子泵抑制剂与低镁血症关系的Meta分析[J]. 山东第一医科大学(山东省医学科学院)学报, 2022, 43(9): 674-681. DOI: 10.3969/j.issn.2097-0005.2022.09.003.
GUO PP, CUI Y, ZHANG RJ, et al. Proton pump inhibitors and hypomagnesemia: a meta-analysis[J]. J ShanDong First Med Univ(ShanDong Acad Med Sci), 2022, 43(9): 674-681. DOI: 10.3969/j.issn.2097-0005.2022.09.003.
|
[38] |
LATEEF JUNAID MA, FARAZ A, VASEEM M, et al. Effect of proton pump inhibitors on magnesium levels in Type II diabetic patients: a single centre study from Saudi Arabia[J]. Eur Rev Med Pharmacol Sci, 2023, 27(3): 1077-1082. DOI: 10.26355/eurrev_202302_31204.
|
[39] |
VAN LAECKE S, VAN BIESEN W. Hypomagnesaemia in kidney transplantation[J]. Transplant Rev (Orlando), 2015, 29(3): 154-160. DOI: 10.1016/j.trre.2015.05.002.
|
[40] |
PANTHOFER AM, LYU B, ASTOR BC, et al. Post-kidney transplant serum magnesium exhibits a U-shaped association with subsequent mortality: an observational cohort study[J]. Transpl Int, 2021, 34(10): 1853-1861. DOI: 10.1111/tri.13932.
|